NCT01696422 - Phase II Trial to Evaluate Safety and Immunogenicity of a Dengue 1,2,3,4 (Attenuated) Vaccine | Biotech Hunter

Enrollment

300

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

April 30, 2016

Study Completion Date

December 31, 2020

Conditions

Dengue

Interventions

BIOLOGICAL

Dengue 1,2,3,4 (attenuated) vaccine

Dose 1000 PFU per virus (1,2,3,4) Route:subcutaneous

BIOLOGICAL

TetraVax-DV Vaccine - Admixture TV003

Dose 1000 PFU per virus (1,2,3,4) Route: subcutaneous

OTHER

Placebo

Route:subcutaneous

Trial Locations (2)

Instituto da Criança do Hospital das Clínicas da Faculdade de Medicina da USP, São Paulo

Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo